Singapore – June 17, 2021 – Cooley advised Engine Biosciences, a company deciphering complex biology to create medicines, on its $43 million Series A financing round. A Cooley team led by Singapore-based partner Matthew Bartus advised Engine Biosciences on the transaction.
Polaris Partners led the round, which also included participation from Invus, 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper and Nest.Bio. Engine Biosciences will use the new capital to expand its portfolio of precision oncology therapeutics, prepare for its first clinical programs and scale its proprietary technology platform.
“We are honored that this preeminent group of life science and technology investors has recognized the progress our team has made and is supporting our mission to unleash new medicines by deciphering biology,” Jeffrey Lu, co-founder and CEO of Engine Biosciences, said in a news release.
Located in Singapore and Silicon Valley, Engine Biosciences operates at the intersection of data science, machine learning, high-throughput biology experimentation, combinatorial genetics, chemistry and drug discovery. Its technologies enable researchers and drug developers to uncover the gene interactions and biological networks underlying diseases faster and more cost-effectively than conventional methods.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,200 lawyers across 17 offices in the United States, Asia and Europe.